Allergan Announces FDA Approval of Juvederm Gel Family of Products

IRVINE, Calif., June 5, 2006 -- Allergan, Inc. today announced
the U.S. Food and Drug Administration (FDA)'s approval of the
Juvederm gel family of products, a 'next generation' of hyaluronic
acid dermal fillers that provide a smooth, long-lasting correction
of facial wrinkles and folds.

Juvederm is natural, biodegradable and currently the only
approved hyaluronic acid dermal filler that has demonstrated its
safety and effectiveness in patients of all skin types and colors.
It also is the only hyaluronic acid dermal filler developed using a
proprietary, technologically advanced manufacturing process that
results in a malleable smooth gel that flows easily into the skin,
creating a smooth, natural look and feel. All other currently
approved hyaluronic acid dermal fillers utilize a gel particle
suspension formulation.

The Juvederm family of products offers the highest concentration
of cross-linked hyaluronic acid available in a dermal filler, which
results in a long duration of effect and may be attributed to the
majority of patients not requiring touch-ups following their
initial treatment. The smooth consistency of the Juvederm formula
also may help to minimize the discomfort that can sometimes occur
during the injection procedure.

The FDA approved three different formulations for Juvederm
providing physicians with the flexibility to tailor each treatment
to the particular needs of the patient. The three product
formulations include: Juvederm 24HV, a highly cross-linked
formulation for more versatility in contouring and volumizing of
facial wrinkles and folds; Juvederm 30HV, a more highly
cross-linked robust formulation for volumizing and correction of
deeper folds and wrinkles; and Juvederm 30, a highly
cross-linked formulation for subtle correction of facial wrinkles
and folds.

Hyaluronic acid dermal fillers represent the fastest growing
non-invasive aesthetic procedure in the United States. Occurring
naturally in the body, hyaluronic acid is a natural complex sugar
found in all living organisms and creates volume and elasticity in
the skin. Juvederm adds volume to facial wrinkles, such as
nasolabial folds (the folds running from the sides of the bottom of
the nose to the outer corners of the mouth). Hyaluronic acid treats
multiple medical conditions, including those associated with the
eye and the knee, and has been used for more than 20 years.

Juvederm Clinical Studies

The FDA's approval of Juvederm was based on data from a
double-blind, randomized and controlled clinical trial. A total of
439 subjects were followed for six months after injection with one
of three Juvederm formulations (Juvederm 24HV, Juvederm 30HV,
Juvederm 30) in one nasolabial fold, and Zyplast (bovine-based
collagen) in the other.

Juvederm was found to provide a more persistent wrinkle
correction than Zyplast over the 6-month course of the study, with
up to 90% of subjects maintaining at least a 1-grade improvement in
nasolabial fold correction with Juvederm compared to 36-45% with
Zyplast. At the conclusion of the study, up to 88% of subjects
expressed a preference for Juvederm while only 5-12% expressed a
preference for Zyplast. In addition, among non-Caucasian patients
(all Fitzpatrick Skin Types), Juvederm was found safe and effective
and demonstrated no increased risk of hyperpigmentation or
hypertrophic scarring.

Important Juvederm Safety Information

In clinical studies, adverse events were usually mild to
moderate in nature, did not require intervention and lasted seven
days or less. The most common side effects included temporary
injection site reactions including redness, pain/tenderness,
firmness, swelling, lumps and bumps and bruising.